+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
ID07563881

Evaluating RAP-219 Tablets for Reducing Focal Seizures in Adults Randomized, Double-blind, Placebo-controlled Phase 3 Study

Led by Rapport Therapeutics Inc. · Updated on 2026-10-26

333

Participants Needed

18

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the investigational drug RAP-219 in adults with focal seizures to determine its safety and effectiveness in reducing the frequency of these seizures. This Phase 3 study involves participants diagnosed with focal epilepsy, aiming to compare different doses of RAP-219 against a placebo. The study is designed as a randomized, double-blind, placebo-controlled trial to rigorously assess treatment outcomes. Participants will be randomly assigned to one of three groups high dose RAP-219, medium dose RAP-219, or placebo, all given as daily oral tablets. After completing the 14-week double-blind treatment period, participants may join an open-label extension study for long-term safety monitoring or enter an 8-week post-treatment follow-up period. This structure helps assess both immediate and ongoing effects of the drug. During the trial, participants will keep daily seizure records using an electronic diary to track focal seizure activity. Researchers will monitor seizure frequency changes from baseline to the end of treatment, focusing on median percent change and responder rates with at least 50% reduction. Additional assessments include seizure-free intervals and safety evaluations throughout the study and follow-up periods, lasting until study completion in 2029.

CONDITIONS

Brief Title

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1

Research Team

R

Rapport Medical

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here